Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price dropped 2.7% on Monday . The stock traded as low as $9.32 and last traded at $9.41, with a volume of 63,329 shares trading hands. The stock had previously closed at $9.67.

OXFD has been the topic of several recent analyst reports. Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. BTIG Research reiterated a “buy” rating and set a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.

The firm’s market cap is $209.44 million. The firm’s 50-day moving average is $8.83 and its 200-day moving average is $9.77.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company earned $19.20 million during the quarter, compared to analyst estimates of $18.10 million. During the same period in the previous year, the company posted ($0.33) EPS. The company’s quarterly revenue was up 34.3% on a year-over-year basis. On average, equities analysts forecast that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current fiscal year.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.